Health Enterprises Network (HEN) and Advanced Manufacturing and Logistics Network (AML) celebrated the graduation of 26 ...
Q3 2025 Management View James Dentzer, President and CEO, emphasized continued progress in the TakeAim Lymphoma study evaluating emavusertib in combination with ibrutinib in primary CNS lymphoma ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to M2T-CD33 (LTI-214) for the treatment of ...
The Investment Adviser Association and the Investment Company Institute voiced support for the two-year postponement, citing a need for tailored anti-money laundering requirements.
M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...
On July 21, 2025, the Financial Crimes Enforcement Network (FinCEN) announced its intention to postpone, for two years, the effective date of a final rule subjecting investment advisers to the ...
FinCEN has postponed the effective date of its AML/CFT rule for investment advisers until January 1, 2028, giving fund managers more time to prepare. The rule would require advisers to adopt bank-like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback